DEPARTMENT OF THE NAVY
BUREAU OF MEDICINE AND SURGERY
WASHINGTON, D.C. 20390

IN REPLY REFER TO

BUMEDINST 6710.49B
BUMED-(NIDRB)
3 May 1967

BUMED INSTRUCTION 6710.49B

From: Chief, Bureau of Medicine and Surgery
To: Stations Having Medical Corps/Dental Corps Personnel

Subj: Investigational drugs; guidelines for handling

Ref: (a) New Drug Regulations, Code of Federal Regulations, Part 130
(b) DOD Instruction 5030.29, dtd 12 May 1964 (NOTAL)
(c) Manual of the Medical Department, Article 20-10 *

1. Purpose. To provide guidelines for the safe handling of investigational drugs and to minimize the chance for misadventure in their use.

2. Cancellation. BUMED Instruction 6710.49A is hereby cancelled and superseded.

3. Definitions

a. FDA. Food and Drug Administration of the U. S. Department of Health, Education, and Welfare.

b. New Drug Regulations. New Drug Regulations as specified in Part 130 of Title 21 of the Code of Federal Regulations.

c. Investigational Drugs. An Investigational Drug is any drug, including a vaccine, a biological or any other agent intended for the cure, mitigation, or prevention of disease, which has not been approved by the FDA for general use but which has been approved for investigational use only.

d. Sponsor. The sponsor of an investigational drug is any individual or organization which, having developed or obtained rights to a new or unapproved drug, applies to the FDA for permission to commission clinical trials of the drug. When the FDA grants such permission, the status of the drug is that of an investigational drug.

e. Investigator. An investigator is any qualified individual designated by the sponsor to perform clinical trials of an investigational drug. He initiates and signs the Form FD 1573.

f. Co-investigator. A co-investigator is any qualified individual designated by the investigator to aid in the performance of clinical

trials of an investigational drug. His name is listed on the Form FD 1573 by the investigator.

4. Forms

a. Form FD 1573. This form is filed with the sponsor by a qualified investigator who will carry out clinical trials of the drug. It is to contain information as described in reference (a).

b. NAVMED 6710/1. Narcotic and Controlled Drug Account Record. This form replaces NAVMED 1398. NAVMED 1398 will continue to be used until existing supplies are exhausted.

c. NAVMED 6710/2. Investigational Drug Data Record. This form replaces NAVMED 1448.

d. NAVMED 6710/3. Investigational Drug Inventory and Prescription Record. This form replaces NAVMED 1449.

5. General.

a. DOD. The Department of Defense assumes full responsibility for the protection of humans involved in research under its sponsorship, whether this involves investigational drugs or other hazards.

* b. BUMED. In accordance with reference (b), the Bureau of Medicine and Surgery has established a Naval Investigational Drug Review Board (NIDRB) to consider each request from within the Navy Medical Department or from its contractors or grantees which may involve the use of human subjects in the clinical investigation of new drugs.

c. Non-Navy Sponsored Drugs. It is expected that most clinical trials performed by Naval personnel will be with drugs sponsored by an organization other than the Navy. The sponsor, in this case, will most often be the pharmaceutical industry. Before a clinical trial with an investigational drug may be performed by Naval personnel with a non-Navy sponsored drug, the following requirements must be met:

(1) In accordance with reference (a), the plan of the test and other pertinent details must be submitted to the Naval Investigational Drug Review Board at BUMED.

(2) The Naval Investigational Drug Review Board must indicate its approval.

(3) The approval of the Naval Investigational Drug Review Board must be confirmed by the Surgeon General of the Navy.

(4) If the approval is confirmed, the investigator will forward * Form FD 1573 to the sponsor, with copy to BUMED (NIDRB, Code 7A).

(5) The addition or deletion of investigators or co-investigators * to the original request for clinical trial of an investigational drug will be accomplished by the submission of an amended Form FD 1573 to the sponsor, with copy to BUMED (NIDRB).

d. Sponsoring of Drugs by the Navy. A practitioner who desires to use a drug not approved for investigational use by the FDA may request the Navy Medical Department to sponsor the drug. Before approval of such sponsorship can be given by the FDA, the following requirements must be met:

(1) The practitioner who will serve as the principal investigator must make his request to the Naval Investigational Drug Review Board via his commanding officer or senior medical officer, as may be appropriate. The request must be accompanied by the following information:

(a) All chemical, generic, and trade names by which the drug is known.

(b) The supplier of the drug.

(c) The dosage form(s) of the drug to be used, including the concentration of all active and inert substances in the preparation.

(d) The route(s) of administration to be used.

(e) The disease condition(s) for which it will be used.

(f) Toxicity data which would indicate, to date, that the drug is safe to use on humans. Such toxicity data may be submitted as such, or by reference to relevant literature. In the event the data is unpublished and is not submitted as such, those having such data must be asked to guarantee its availability to the FDA.

(g) Indication that the use of the drug would be under the supervision of qualified investigators.

(h) The plan of the investigation and other pertinent details as indicated in reference (c).

(2) The Naval Investigational Drug Review Board must indicate its approval.

(3) The approval of the Naval Investigational Drug Review Board must be confirmed by the Surgeon General of the Navy.

(4) The Surgeon General of the Navy must communicate the intent of the Navy's sponsorship of the drug to the Secretary of Health, Education, and Welfare, For the Commissioner of Food and Drugs.

* e. A summary report of the results of the use of an investigational drug must be submitted to the Naval Investigational Drug Review Board annually and at the end of the study period. Any untoward side effects must be reported immediately to the Naval Investigational Drug Review Board.

f. All reports to pharmaceutical firms or other non-Navy sponsors must be submitted via the Naval Investigational Drug Review Board.

g. Reports submitted under this instruction shall serve to fulfill the reporting requirements of reference (c).

6. Urgent Situations

a. Urgent situations may arise when a practitioner feels that emergency use of an investigational drug is indicated in the case of one patient where maintenance of life or vital function is threatened. The following procedures should be used for procurement and use of an investigational drug in such a circumstance.

(1) Approval of the Medical Commanding Officer or Senior Medical Officer, as appropriate.

* (2) BUMED authorization and guidance should be obtained by calling the Senior Member of the Naval Investigational Drug Review Board. The Senior Member or his designee may be contacted via the BUMED Information Desk during working hours, or the BUMED Duty Officer outside of normal working hours (Area Code 202, Oxford 6-7275).

b. If the use of the investigational drug has been agreed upon, the Senior Member will advise the investigator as to the procedures to follow regarding supply of the drug and regulatory requirements. The Senior Member will use the following guidelines:

(1) He may enlist the aid of a civilian or military practitioner, who has been formally designated by the sponsor as an investigator for the drug, to oversee the use of the drug in the emergency situation.

* (2) He may advise the requester to call the sponsor for approval and supply of the drug with the submission of a Form FD 1573 as soon thereafter as possible, with copy to BUMED (NIDRB, Code 7A).

(3) He may advise the investigator to use any other procedure which, in the opinion of the Senior Member, accounts for the interests of the patient, the Navy Medical Department, and government regulations.

(4) He will request the investigator to confirm the telephone call with an official request in writing to BUMED (NIDRB). *

c. Authorization for emergency use of an investigational drug should not be construed as being authorization for use in other patients.

d. At the termination of the use of the drug, a report as to results must be filed with the Naval Investigational Drug Review Board.

7. Classified Drugs

a. For clinical investigations that are classified for reasons of national security, the filing of a formal "Claim for Exemption" (Form FD 1571) to the Department of Health, Education, and Welfare is not required, provided the study has been approved by the Naval Investigational Drug Review Board and the Surgeon General of the Navy.

b. The Bureau of Medicine and Surgery will report periodically to the Food and Drug Administration findings associated with such studies, but only to Food and Drug Administration personnel who have proper security clearance.

8. Principles. Since hospitals are the primary centers for clinical investigation of drugs, the hospitals and the medical staffs have an obligation to their patients to see that proper procedures are established.

a. Investigational drugs should be used only under the direct supervision of the principal staff investigator who should assume the burden of securing the necessary consent and assure that such investigations are performed in strict compliance with the New Drug Regulations and within the framework of the study approved by BUMED.

b. Nurses may administer investigational drugs only under the supervision of an investigator or co-investigator. Nurses who administer investigational drugs should be provided with such basic information as dosage forms, strengths available, actions and uses, side-effects, and symptoms of toxicity.

c. The pharmacy service should store, properly label, and dispense investigational drugs in accord with the investigator's written orders.

9. Guideline Procedures. The following procedures should be adopted for the control and use of investigational drugs, with any modifications necessary to meet the individual needs of the hospital or medical facility.

a. Requests for use of the drugs shall be approved by a pharmacy and therapeutics committee or a clinical research committee prior to submission to BUMED for final approval.

b. The drugs shall be shipped directly from the manufacturer, in the name of the investigator, to the pharmacy, to assure safekeeping under proper storage and for record-keeping procedures.

c. Upon receipt, the pharmacy staff, with the assistance of the investigator, shall prepare a NAVMED 6710/2, Investigational Drug Data Record.

d. The pharmacy shall attach to each container a distinctive label (color or shape) containing the statement, "Investigational Drug - Not for General Use," and the name of the drug (or if a code number is used, then the pharmacological classification; for example, "Analgesic Drug" or "Antihistaminic Drug").

e. The pharmacy shall allocate a separate locked area for the exclusive storage of the drugs.

f. The principal investigator, or authorized practitioner designated by him, shall request the drug from the pharmacy by means of a written prescription form.

g. The prescription shall be kept in a separate file, numbered consecutively, and the number prefixed by "ID".

h. A separate NAVMED 6710/3, Investigational Drug Inventory and Prescription Record, shall be maintained in the pharmacy for each drug. This provides a perpetual pharmacy inventory and serves as a ready reference of all patients receiving the drug.

i. When the drug is delivered to the ward, a completed copy of the NAVMED 6710/2, Investigational Drug Data Record, and a NAVMED 6710/1, Narcotic and Controlled Drug Account Record, shall be delivered to the ward nurse and a receipt shall be obtained. This will assure strict accountability and a perpetual inventory for all drugs on the wards. Nursing personnel shall be responsible for returning unused drugs and the completed NAVMED 6710/1 (1398) to the pharmacy.

j. The pharmacy shall dispose of (by return to the manufacturer or by destruction, as indicated) all drugs no longer in use or for which future use is not anticipated.

k. If "double blind" studies or any other studies requiring coding are utilized, a copy of the code shall be in the pharmacy.

* 10. Implementing Instructions. Hospitals are required to forward one copy of implementing instruction to BUMED (NIDRB).

11. Report Symbol. The report, Results of Use of Investigational Drug, required by paragraphs 5e and 6d, is assigned Report Symbol MED-6710-2.

12. Availability of Forms

a. NAVMED 6710/1 may be obtained from appropriate forms supply distribution points in the Navy Supply System. NAVMED 6710/2 and 6710/3 may be obtained from the Bureau of Medicine and Surgery (Code 3113).

b. Form FD 1573 may be obtained from:

Food and Drug Administration
Administrative Services Branch
Publication Section
Washington, D.C. 20204

R. B. BROWN

Copy to:
M28 (NSD Phila only)

Stocked:
Supply & Fiscal Department (Code 514.32)
U. S. Naval Station, Washington, D.C. 20390